Clinical Trial

Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

Name: Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3) — clinical trial record (NCT07715084)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).

Trial Details

NCT Number	NCT07715084
Lead Sponsor	Azafaros B.V.
Conditions	Gaucher Disease Type 3
Enrollment	20 participants
Start Date	2026-09-28
Primary Completion	2028-01 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-20